Key facts
- Ohara’s last known valuation is $214.3M (Jun 2025).
- It has raised $69.2M; the latest was Seed Round ($69.2M) in Jun 2025.
- Notable investors include JIC Venture Growth Investments, LINK-J, Regional Medical Revitalization Healthcare Fund Investment Business.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Ohara
- ·The full record, as it builds
Funding rounds
No funding rounds for Ohara are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ohara
Manufacturer of prescription medicines intended to address rare and specialized medical conditions. The company develops, manufactures, and distributes pharmaceutical products including treatments for rare diseases, oncology, leukemia, liver related disorders, and selected generics, with activities covering research, clinical development, regulatory compliance, enabling hospitals, healthcare providers, and patients to access reliable medicines that support treatment continuity, medical safety, and affordability within regulated healthcare systems.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 1964
- Employees
- 468
- Website
- ohara-ch.co.jp/
- Ownership
- Privately Held (backing)
Ohara doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ohara shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ohara in its N-PORT filings yet. We sweep new filings monthly.